Crossmark

High expression of signal regulatory protein beta 2 marks a favourable prognostic AML subgroup and associates with increased sensitivity to phagocytosis

Crossref DOI link: https://doi.org/10.1007/s12026-025-09659-w

Published Online: 2025-06-25

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Visser, Nienke

van der Meer, Nisha K.

He, Yuan

Huls, Gerwin

Schuringa, Jan Jacob

Bremer, Edwin
Funding

Funding for this research was provided by:

HORIZON EUROPE Marie Sklodowska-Curie Actions (813871, 813871)
License Information

Text and Data Mining valid from 2025-06-25

Version of Record valid from 2025-06-25
More Information

Article History

Received: 10 April 2025

Accepted: 14 June 2025

First Online: 25 June 2025

Declarations

:

: Peripheral blood (PB) and bone marrow (BM) samples of AML patients were studied after informed consent and protocol approval by the Medical Ethical committee of the UMCG in accordance with the Declaration of Helsinki (protocol code NL43844.042.13, 6 January 2014).

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below